Хронические фиброзирующие интерстициальные заболевания легких с прогрессирующим фенотипом

Проблема фиброзирующих интерстициальных заболеваний легких (ИЗЛ) объединяет специалистов разных областей: пульмонологов, рентгенологов, терапевтов, ревматологов, профпатологов и др. Современные достижения в изучении фиброзирующих ИЗЛ, связанные с разработкой иммунологических и молекулярнобиологических методов определения биомаркеров, новых принципов имидж-диагностики патологии легких, поиском новых терапевтических «мишеней», диктуют необходимость интеграции знаний специалистов различных областей медицины для совершенствования алгоритмов фармакотерапии, направленных на подавление прогрессирования фиброза легких при ИЗЛ, улучшение качества и увеличение продолжительности жизни пациентов.

1. Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020;383(10):958-968. DOI: 10.1056/NEJMra2005230

2. Wong AW, Ryerson CJ, Guler SA. Progression of fibrosing interstitial lung disease. Respir Res. 2020;21(1):32. DOI: 10.1186/s12931-020-1296-3

3. George PM, Spagnolo P, Kreuter M, et al.; Erice ILD working group. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020;8(9):925-934. DOI: 10.1016/S2213-2600(20)30355-6

4. Vancheri C, Basile A. Multidisciplinary approach to interstitial lung diseases: Nothing is better than all of us together. Diagnostics (Basel). 2020;10(7):488. DOI: 10.3390/diagnostics10070488

5. Furini F, Carnevale A, Casoni GL, et al. The role of the multidisciplinary evaluation of interstitial lung diseases: systematic literature review of the current evidence and future perspectives. Front Med (Lausanne). 2019;6:246. DOI: 10.3389/fmed.2019.00246

6. Elicker BM, Kallianos KG, Henry TS. The role of high-resolution computed tomography in the follow-up of diffuse lung disease. Eur Resp Rev. 2017;26(144):170008. DOI: 10.1183/16000617.0008-2017

7. Walsh SLF, Devaraj A, Enghelmayer JI, et al. Role of imaging in progressive-fibrosing interstitial lung diseases. Eur Resp Revc. 2018;27(150):180073. DOI: 10.1183/16000617.0073-2018

8. Chanda D, Otoupalova E, Smith SR, et al. Developmental pathways in the pathogenesis of lung fibrosis. Mol Aspects Med. 2019;65:56-69. DOI: 10.1016/j.mam.2018.08.004

9. Wijsenbeek M, Kreuter M, Olson A, et al. Progressive fibrosing interstitial lung diseases: Current practice in diagnosis and management. Curr Med Res Opin. 2019;35(11):2015-2024. DOI: 10.1080/03007995.2019.1647040

10. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: Incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2(7):566-572. DOI: 10.1016/S2213-2600(14)

11. Kolb M, Vas;ikov;i M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20(1):57. DOI: 10.1186/s12931-019-1022-1

12. Насонов ЕЛ, Александрова ЕН, Новиков АА. Аутоимунные ревматические заболевания - проблемы иммунопатологии и персонифицированной терапии. Вестник РАМН. 2015;(2):169-182. DOI: 10.15690/vramn.v70i2.1310

13. Goldblatt F, O'Neill SG. Clinical aspects of autoimmune rheumatic diseases. Lancet. 2013;382(9894):797-808. DOI: 10.1016/S0140-6736(13)61499-3

14. Atzeni F, Gerardi MC, Barilaro G, et al. Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. Expert Rev Clin Immunol. 2018;14(1):69-82. DOI: 10.1080/1744666X.2018.1411190

15. Fischer A, Distler J. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clin Rheumatol. 2019;38(10):2673-2681. DOI: 10.1007/s10067-019-04720-0

16. Sambataro D, Sambataro G, Pignataro F, et al. Patients with interstitial lung disease secondary to autoimmune diseases: How to recognize them? Diagnostics (Basel). 2020;10(4):208. DOI: 10.3390/diagnostics10040208

17. Perelas A, Silver RM, Arrossi AV, et al. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(3):304-320. DOI: 10.1016/S2213-2600(19)30480-1

18. Barba T, Mainbourg S, Nasser M, et al. Lung diseases in inflammatory myopathies. Semin Respir Crit Care Med. 2019;40(2):255-270. DOI: 10.1055/s-0039-1685187

19. Hervier B, Uzunhan Y. Inflammatory myopathy-related interstitial lung disease: From pathophysiology to treatment. Front Med (Lausanne). 2020;6:326. DOI: 10.3389/fmed.2019.00326

20. Betteridge Z, Tansley S, Shaddick G, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019;101:48-55. DOI: 10.1016/j.jaut.2019.04.001

21. Long K, Danoff SK. Interstitial lung disease in polymyositis and dermatomyositis. Clin Chest Med. 2019;40(3):561-572. DOI: 10.1016/j.ccm.2019.05.004

22. Gonzdlez-Moreno J, Raya-Cruz M, Losada-Lopez I, et al. Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: A case report and literature review. Rheumatol Int. 2018;38(7):1293-1296. DOI: 10.1007/s00296-018-3991-7

23. Ciang NC, Pereira N, Isenberg DA. Mixed connective tissue disease - enigma variations? Rheumatology (Oxford). 2017;56(3):326-333. DOI: 10.1093/rheumatology/kew265

24. Perelas A, Arrossi AV, Highland KB. Pulmonary manifestations of systemic sclerosis and mixed connective tissue disease. Clin Chest Med. 2019;40(3):501-518. DOI: 10.1016/j.ccm.2019.05.001

25. Spagnolo P, Lee JS, Sverzellati N, et al. The lung in rheumatoid arthritis: Focus on interstitial lung disease. Arthritis Rheumatol. 2018;70(10):1544-1554. DOI: 10.1002/art.40574

26. Bendstrup E, M0ller J, Kronborg-White S, et al. Interstitial lung disease in rheumatoid arthritis remains a challenge for clinicians. J Clin Med. 2019;8(12):2038. DOI: 10.3390/jcm8122038

27. Wu EK, Ambrosini RD, Kottmann RM, et al. Reinterpreting evidence of rheumatoid arthritis-associated interstitial lung disease to understand etiology. Curr Rheumatol Rev. 2019;15(4):277-289. DOI: 10.2174/1573397115666190116102451

28. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir Med. 2020;8(8):807-815. DOI: 10.1016/S2213-2600(20)30225-3

29. Spagnolo P, Balestro E, Aliberti S, et al. Pulmonary fibrosis secondary to COVID-19: A call to arms? Lancet Respir Med. 2020;8(8):750-752. DOI: 10.1016/S2213-2600(20)30222-8

30. Mira-Avendano I, Abril A, Burger CD, et al. Interstitial lung disease and other pulmonary manifestations in connective tissue diseases. Mayo Clin Proc. 2019;94:309-325. DOI: 10.1016/j.mayocp.2018.09.002

31. Акулкина ЛА, Бровко МЮ, Шоломова ВИ, и др. Интерстициальная пневмония с аутоиммунными признаками (ИПАП): мультидисциплинарный диагноз в пульмонологии и ревматологии. Клиническая фармакология и терапия. 2018;18(27):5-10.

32. Graney BA, Fischer A. Interstitial pneumonia with autoimmune features. Ann Am Thorac Soc. 2019;16(5):525-533. DOI: 10.1513/AnnalsATS.201808-565CME

33. Wilfong EM, Lentz RJ, Guttentag A, et al. Interstitial pneumonia with autoimmune features: An emerging challenge at the intersection of rheumatology and pulmonology. Arthritis Rheumatol. 2018;70(12):1901-1913. DOI: 10.1002/art.40679

34. Adegunsoye A, Oldham JM, Bellam SK, et al. Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases. Ann Am Thorac Soc. 2019;16(5):580-588. DOI: 10.1513/AnnalsATS.201807-443OC

35. Wollin L, Distler JHW, Redente EF, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019;54(3):1900161. DOI: 10.1183/13993003.001612019

36. Landi C, Bergantini L, Cameli P, et al. Idiopathic pulmonary fibrosis serum proteomic analysis before and after nintedanib therapy. Sci Rep. 2020;10:9378. DOI: 10.1038/s41598-020-66296-z

37. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082. Erratum in: N Engl J Med. 2015;373(8):782. DOI: 10.1056/NEJMoa1402584

38. Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: Results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019;7(1):60-68. DOI: 10.1016/S2213-2600(18)30339-4

39. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518-2528. DOI: 10.1056/NEJMoa1903076

40. Seibold JR, Maher TM, Highland KB, et al. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: Data from the SENSCIS trial. Ann Rheum Dis. 2020;79(11):1478-1484. DOI: 10.1136/annrheumdis-2020-217331

41. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718-1727. DOI: 10.1056/NEJMoa1908681

42. Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8(5):453-460. DOI: 10.1016/S2213-2600(20)30036-9

43. Авдеев СН, Ананьева ЛП, Жиляев ЕВ, и др. Резолюция Совета экспертов, посвященного теме «Интерстициальные заболевания легких при системной склеродермии» (14 октября 2019 г., Москва). Современная ревматология. 2020;14(1):125-128. DOI: 10.14412/1996-7012-2020-1-125-128.

44. Sinha A, Patel AS, Siegert RJ, et al. The King's Brief Interstitial Lung Disease (KBILD) questionnaire: An updated minimal clinically important difference. BMJ Open Respir Res. 2019;6(1):e000363. DOI: 10.1136/bmjresp-2018-000363

45. Liu R, Lei C, Liao X, et al. Semi-quantitative analysis for the dynamic chest CT imaging features from onset to recovery in severe and critical COVID-19. Radiol Infect Dis. 2020;7(3):114-122. DOI: 10.1016/j.jrid.2020.07.003